Structure Therapeutics, Inc. (GPCR)

35.90 -0.12 (-0.33%) USD  |  NASDAQ  |  Sep 25, 16:00
35.90 0.00 (0.00%) After-Hours: 19:28
More

Structure Therapeutics Research and Development Expense (Annual) : 225.85M for Dec. 31, 2025

Research and Development Expense (Annual) Chart

View Research and Development Expense (Annual) for GPCR.
Upgrade now.
Sep '18
Jan '19
May '19
 
285.00
270.00
255.00
240.00
View Research and Development Expense (Annual) Chart
Start Trial

Historical Research and Development Expense (Annual) Data

View and export this data back to 2020. Start Trial.
Date Value
December 31, 2025 225.85M
December 31, 2024 108.87M
December 31, 2023 70.04M
Date Value
December 31, 2022 36.15M
December 31, 2021 29.15M
December 31, 2020 12.39M

R&D Expense Definition

R&D expense is a line item from many companies' income statements.

Read full definition.

Research and Development Expense (Annual) Range, Past 5 Years

View Research and Development Expense (Annual) Range, Past 5 Years
Start Trial
--
Minimum
--
Maximum
--
Average
--
Median

Research and Development Expense (Annual) Benchmarks

View Research and Development Expense (Annual) Benchmarks
Start Trial
Eli Lilly & Co. 13.34B
Novo Nordisk A/S 6.838B
Pfizer Inc. 10.25B
Johnson & Johnson 14.83B
Merck & Co., Inc. 12.51B